Board

Tim Hirst, PhD

Tim is the Chairman & CEO of GPN Vaccines. He has extensive expertise in the life sciences, executive management and venture capital investment. Tim was previously CEO of ANU Connect Ventures, a $30M pre-seed VC fund, the Deputy Vice Chancellor for Research & Innovation at The University of Sydney and Professor & Head of Microbiology at the University of Bristol, UK. He is an active angel investor working with investment groups throughout Australia and US to assist early stage companies to raise capital and develop their innovative technologies. Tim is also Chairman of Gamma Vaccines Pty Ltd, Brain Changer Pty Ltd, Flex-G Pty Ltd, Acting Chairman of Emudent Technologies Pty Ltd, Trustee Director of Griffin Accelerator Holdings Pty Ltd and an Honorary Adjunct Professor at the University of Adelaide.

James Paton, PhD FAA

James is a Professor of Microbiology and the Director of the Research Centre for Infectious Diseases at the University of Adelaide. He is Australia’s preeminent authority on the pathogenesis of S. pneumoniae and recently was South Australian Scientist of the Year (2017). James is a former NHMRC Australia Fellow and Senior Principle Research Fellow and he directs an internationally acclaimed team of researchers at the University of Adelaide. He has published over 370 research papers and in the last 8 years has raised over $36M in grants to support his research activities. James was the lead Chief Investigator on the ARC Linkage grant that led to the development of the Gamma-PN vaccine and the NHMRC Development Grant that is supporting its final preclinical development.

Barry Palte, FIA

Barry is Chairman of EQ Capital Partners, a Social Impact Investment group headquartered in Sydney. He is also Chief Investment Officer of Contour Companies (a Detroit USA headquartered social housing group), a member of Top Tier Impact (a Geneva headquartered Social Impact investment group) and a member of the Global Investment Leaders Club (a Dubai headquartered family office organisation). He was previously Global Chairman of the International Association of Investment Bankers (now renamed Orion International Advisors) and was Head of Mergers, Acquisitions and Strategic Development for the fund’s management business of Australia’s largest Bank, Commonwealth Bank of Australia.

Martin Goetting

Martin is the General Manager of Capricorn Consilium GmbH (Ltd.) – a Vienna–based consulting and interim management company. Martin has extensive experience in the vaccine pharma-industry with over 20 years at Behringwerke AG/Chiron Vaccines International, including as Global Head of Production and Sales Logistics and as Director Commercial Operations. He was also VP Marketing, Sales & Supply at Intercell AG (today Valneva), a company focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases.

Mohammed Alsharifi, PhD

Mohammed is a Senior Lecturer in Virology & Immunology at The University of Adelaide and Chief Scientific Officer of Gamma Vaccines Pty Ltd. Mohammed brings a wealth of experience in the use of gamma-irradiation to inactivate viral and bacterial pathogens and he was a Chief Investigator on the ARC Linkage grant that led to the development of the Gamma-PN vaccine program and the NHMRC Development Grant that is supporting its final preclinical development.

Ismail Kola, PhD

Ismail is a Senior Partner at Forepont Capital, a New York-based venture capital firm investing in pharmaceutical and biotechnology companies that improve healthcare outcomes. He has held several senior executive positions at UCB, Merck, Schering-Plough and Pharmacia Corporation. Throughout Ismail’s distinguished career, he has led teams that have successfully brought numerous blockbuster pharmaceutical products to market, with several others currently in pivotal development. Prior to his move to industry, Ismail was Professor of Human Molecular Genetics at Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease.

Protecting children and adults from the world’s foremost bacterial pathogen